Diplomat Pharmacy (NYSE:DPLO) Receives New Coverage from Analysts at Deutsche Bank

Deutsche Bank assumed coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a report released on Thursday, BenzingaRatingsTable reports. The firm issued a sell rating and a $4.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a sell rating in a research report on Wednesday, August 14th. ValuEngine upgraded Diplomat Pharmacy from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Wells Fargo & Co raised their price target on Diplomat Pharmacy from $5.00 to $5.50 and gave the company a market perform rating in a research report on Tuesday, August 13th. Finally, Barclays set a $7.00 price target on Diplomat Pharmacy and gave the company a buy rating in a research report on Friday, August 9th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Hold and an average price target of $9.43.

NYSE:DPLO traded down $0.35 during trading hours on Thursday, hitting $5.64. The company’s stock had a trading volume of 86,116 shares, compared to its average volume of 740,879. The business’s 50-day moving average is $5.60 and its two-hundred day moving average is $5.55. The company has a market capitalization of $502.00 million, a PE ratio of 28.35 and a beta of 1.01. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99. Diplomat Pharmacy has a 52-week low of $4.17 and a 52-week high of $21.48.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.23 billion. During the same quarter in the previous year, the company posted ($0.05) EPS. The company’s revenue was down 9.1% compared to the same quarter last year. As a group, analysts predict that Diplomat Pharmacy will post -0.78 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of DPLO. Stephens Inc. AR increased its position in Diplomat Pharmacy by 1,482.3% during the 2nd quarter. Stephens Inc. AR now owns 6,600,015 shares of the company’s stock worth $40,194,000 after purchasing an additional 6,182,889 shares in the last quarter. JPMorgan Chase & Co. increased its position in Diplomat Pharmacy by 390.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,445,834 shares of the company’s stock worth $8,632,000 after purchasing an additional 1,150,740 shares in the last quarter. BlackRock Inc. increased its position in Diplomat Pharmacy by 7.2% during the 2nd quarter. BlackRock Inc. now owns 9,154,249 shares of the company’s stock worth $55,749,000 after purchasing an additional 614,918 shares in the last quarter. Invesco Ltd. increased its position in Diplomat Pharmacy by 53.4% during the 2nd quarter. Invesco Ltd. now owns 1,220,554 shares of the company’s stock worth $7,433,000 after purchasing an additional 424,647 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Diplomat Pharmacy by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock worth $28,650,000 after purchasing an additional 395,246 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

See Also: Buyback

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit